E
VTGN icon

Ergoteles’s VistaGen Therapeutics VTGN Stock Holding History

Ergoteles’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-983
Closed -$26K – 2024
2022
Q2 		$26K Buy
+983
New +$34.7K ﹤0.01% 1577
2022
Q1 		– Sell
-3,428
Closed -$201K – 1656
2021
Q4 		$201K Buy
+3,428
New +$223K 0.01% 1035

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ergoteles's VTGN Position: Q3 2022 in Review

Ergoteles sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 983 shares — an estimated $26K sold.

Ergoteles first reported a position in VTGN in Q4 2021 and held it in 2 quarters. The position peaked at $201K in Q4 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • Ergoteles reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 983 VistaGen Therapeutics shares in Q3 2022, an estimated $26K.
  • Ergoteles first reported a position in VistaGen Therapeutics in Q4 2021 and held it in 2 quarters.
  • Ergoteles's VistaGen Therapeutics position peaked at $201K in Q4 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.